Platelet Anti-Aggregating Triterpenoids from the Leaves of<i>Acanthopanax senticosus</i>and the Fruits of<i>A. sessiliflorus</i>

Jin, Jing Ling; Lee, Sang‐Hyun; Lee, Yong Yook; Kim, Jeong Mi; Heo, Jung Eun; Yun‐Choi, Hye Sook

doi:10.1055/s-2004-827159

Cited by 38 publications

(20 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The young leaves of A. senticosus are cultivated as a vegetable crop in Northeast China. As regards biological active constituents of A. senticosus , many of its triterpenoid saponins [1,2,3,4] were reported to have anti-inflammatory [5], antibacterial [6] and platelet anti-aggregating activities [7]. Our studies indicated that the 30% EtOH fraction of A. senticosus leaves can inhibit plasma glucose levels in alloxan-induced diabetic rats and showed significant α -glucosidase inhibition activity.…”

Section: Introductionmentioning

confidence: 72%

α-Glucosidase Inhibitory Constituents from Acanthopanax senticosus Harm Leaves

et al. 2012

View full text Add to dashboard Cite

A new triterpene glycoside, 3-O-[(α-L-rhamnopyranosyl)(1→2)]-[β-D-glucuronopyranosyl-6-O-methyl ester]-olean-12-ene-28-olic acid (1) and a new indole alkaloid, 5-methoxy-2-oxoindolin-3-acetic acid methyl ester (5) were isolated from the leaves of Acanthopanax senticosus Harms along with six known compounds. The structures of the new compounds were determined by means of 2D-NMR experiments and chemical methods. All the isolated compounds were evaluated for their glycosidase inhibition activities and compound 6 showed significant α-glucosidase inhibition activity.

show abstract

Section: Introductionmentioning

confidence: 72%

α-Glucosidase Inhibitory Constituents from Acanthopanax senticosus Harm Leaves

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Our previous study has shown that Acanthopanax sessiliflorus exhibited both antithrombotic and antiplatelet activities in vivo on rats (Song et al, 2011). Triterpenoids isolated from Acanthopanax sessiliflorus showed antiplatelet aggregation activity (Jin et al, 2004;Yang et al, 2009). Furthermore, this plant has been developed into a series of products for food therapy in China and Korea.…”

mentioning

confidence: 99%

LC–MS/MS determination and pharmacokinetic study of four lignan components in rat plasma after oral administration of Acanthopanax sessiliflorus extract

Song

Deng

Huang

et al. 2012

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…The naturally occurring triterpenoid, oleanolic acid, has been shown to induce concentration-dependent platelet aggregation, possibly through a phospholipase C-mediated calcium mobilization mechanism [20]. On the other hand, several other naturally occurring triterpenoids have demonstrated anti-platelet aggregation activity [21-24] possibly through down-regulation of phosphorylated ERK [23]. In hepatocellular stellate cells, triterpenoid appears to decrease phosphorylation of PDGF-R and AKT [25].…”

Section: Discussionmentioning

confidence: 99%

Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors

Speranza

Gutierrez

Kummar

et al. 2011

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Background The triterpenoid 2-Cyano-3, 12-Dioxoolean-1, 9-Dien-28-Oic Acid (CDDO, previously RTA-401) is a multifunctional molecule that controls cellular growth and differentiation. It is capable of activating the transcription factor peroxisome proliferator activator receptor-γ (PPARγ) and inducing apoptosis in malignant cells in vitro and in vivo. We conducted a phase I dose-escalation study to determine the toxicity, the maximum tolerated dose, and the pharmacokinetics and pharmacodynamics of CDDO, administered as a 5-day continuous infusion every 28 days in patients with advanced cancers. Methods An accelerated titration design was followed, with one patient per cohort entered, and doses ranging from 0.6 mg/m2/hr to 38.4 mg/m2/hr. Pharmacokinetics of CDDO was assessed and cleaved poly (ADP-ribose) polymerase (c-PARP), as a marker of apoptosis, was measured in peripheral blood mononuclear cells to assess drug effect. Results Seven patients, one patient per dose level up to dose level 7 (38.4 mg/m2/hr), were enrolled and received a total of 11 courses of treatment. Cmax increased proportionally with dose. Preclinically determined efficacious blood level (1 μM) of drug was attained at the highest dose level. One patient, at dose level 6, experienced grade 2 mucositis, nausea, vomiting, and anorexia. Four patients, on different dose levels, developed thromboembolic events subsequently considered as dose-limiting toxicity. No anti-tumor activity was noted. Conclusion A causal relationship of observed thromboembolic events to CDDO was considered possible but could not be established. Because of the adverse events and the development of an orally bioavailable derivative compound, CDDO methyl ester, this trial was terminated.

show abstract

Platelet Anti-Aggregating Triterpenoids from the Leaves ofAcanthopanax senticosusand the Fruits ofA. sessiliflorus

Cited by 38 publications

References 11 publications

α-Glucosidase Inhibitory Constituents from Acanthopanax senticosus Harm Leaves

α-Glucosidase Inhibitory Constituents from Acanthopanax senticosus Harm Leaves

LC–MS/MS determination and pharmacokinetic study of four lignan components in rat plasma after oral administration of Acanthopanax sessiliflorus extract

Phase I study of the synthetic triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid (CDDO), in advanced solid tumors

Contact Info

Product

Resources

About